Research Square,

Richard Schasfoort, Jos van Weperen, Margot van Amsterdam, Judicaël Parisot, Jan Hendriks, Michelle Koerselman, Marcel Karperien, Anouk Mentink, Martin Bennink, Hans Krabbe, Leon Terstappen, Leontine Mulder


Surface Plasmon Resonance imaging (SPRi) was used to determine the presence and strength of binding of IgG, IgM and IgA against the Receptor Binding Domain (RBD) of SARS-CoV-2 in sera of 119 COVID-19 patients. The high-throughput assay enables to follow the specific immune response of ultimate 384 individuals for these four parameters in one run. The measured IgG, IgM and IgA levels correlated with ELISA (Euroimmun: Anti-SARS-CoV-2, IgG assay, r-0.95, ECLIA: Anti-SARS-CoV-2 Ig electrochemiluminescence r=0.73). During the course of the disease, the IgG levels and strength of binding increased while generally the IgM and IgA levels went down. Recovered patients all show high strength of binding of the IgG type to the RBD protein. The anti-RBD immune globulins SPRi assay provides additional insights in the immune status of patients recovering from COVID-19 and can be applied for the assessment of the immune reaction of healthy individuals in vaccination programmes.